Ocrelizumab Benefits in MS Maintained to 96 Weeks Medscape Rituximab, an anti-CD20 monoclonal antibody that selectively reduces CD20-positive B-cells, showed "proof of concept" efficacy in MS in phase 1 and 2 investigations, they say. Ocrelizumab is a recombinant humanized version of rituximab meant to provide ... |
